Valuation: IN8bio, Inc.

Market Cap 12.77M 11.24M 10.65M 9.62M 18.12M 1.22B 18.36M 127M 49.04M 626M 47.94M 46.89M 2.01B P/E 2026 *
-1.16x
P/E 2027 * -1.36x
Enterprise Value 12.77M 11.24M 10.65M 9.62M 18.12M 1.22B 18.36M 127M 49.04M 626M 47.94M 46.89M 2.01B EV / Sales 2026 *
-
EV / Sales 2027 * 11.5x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day+4.63%
1 week+21.88%
Current month+21.88%
1 month+21.88%
3 months-4.91%
6 months-2.14%
Current year-42.71%
1 week 1.1
Extreme 1.1
1.36
1 month 1.01
Extreme 1.01
1.36
Current year 0.88
Extreme 0.88
2.73
1 year 0.88
Extreme 0.88
2.73
3 years 0.88
Extreme 0.88
74.4
5 years 0.88
Extreme 0.88
282.72
10 years 0.88
Extreme 0.88
309.57
Manager TitleAgeSince
Chief Executive Officer 50 01/11/2015
Chief Tech/Sci/R&D Officer 72 01/11/2018
Director of Finance/CFO 43 08/02/2021
Director TitleAgeSince
Director/Board Member 50 01/11/2015
Director/Board Member 68 01/07/2019
Director/Board Member 64 04/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Don

Director

-724,637 7.3589%
09/05/26 Free

Chairman

22,000 0.2234%
09/05/26 Free

Director

22,000 0.2234%
Change 5-day change 1-year change 3-year change Capi.($)
+3.53%+21.88%-38.22%-95.70% 12.77M
+4.16%-0.30%+58.96%+94.17% 71.53B
-0.19%+1.32%+37.20%+81.33% 60.12B
-1.51%+2.39%+9.10%+36.79% 48.85B
+0.06%+0.59%+41.86%+38.97% 44.28B
+1.01%+8.65%+343.78%+691.92% 43.83B
+0.35%+1.05%+8.26%+106.64% 41.53B
-0.67%-0.45%+4.47%+46.37% 30.13B
+4.77%+6.46%+41.54%+22.78% 27.98B
-0.77%-2.64%-20.00%+354.14% 25.25B
Average +1.22%+3.23%+48.70%+137.74% 39.35B
Weighted average by Cap. +0.98%+1.22%+63.41%+154.70%

Financials

2026 *2027 *
Net sales - 1.11M 974K 923K 833K 1.57M 106M 1.59M 11.04M 4.25M 54.23M 4.15M 4.06M 174M
Net income -20.96M -18.46M -17.49M -15.79M -29.76M -2.01B -30.15M -209M -80.53M -1.03B -78.72M -77M -3.29B -23.72M -20.89M -19.79M -17.87M -33.68M -2.27B -34.12M -237M -91.14M -1.16B -89.09M -87.14M -3.73B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
30/09/26 $1.341 +3.53% 27,759
29/09/26 $1.295 +4.44% 62,212
28/09/26 $1.240 +3.33% 74,348
25/09/26 $1.200 +0.84% 67,589
24/09/26 $1.190 +8.18% 180,130
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.295USD
Average target price
7.000USD
Spread / Average Target
+440.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock